CELC
Price
$13.86
Change
+$0.08 (+0.58%)
Updated
Jul 16 closing price
Capitalization
524.83M
21 days until earnings call
CLRB
Price
$5.22
Change
+$0.18 (+3.57%)
Updated
Jul 17, 11:54 AM (EDT)
Capitalization
14.4M
32 days until earnings call
Interact to see
Advertisement

CELC vs CLRB

Header iconCELC vs CLRB Comparison
Open Charts CELC vs CLRBBanner chart's image
Celcuity
Price$13.86
Change+$0.08 (+0.58%)
Volume$296.53K
Capitalization524.83M
Cellectar Biosciences
Price$5.22
Change+$0.18 (+3.57%)
Volume$100
Capitalization14.4M
CELC vs CLRB Comparison Chart in %
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. CLRB commentary
Jul 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Buy and CLRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 17, 2025
Stock price -- (CELC: $13.86 vs. CLRB: $5.04)
Brand notoriety: CELC and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 118% vs. CLRB: 25%
Market capitalization -- CELC: $524.83M vs. CLRB: $14.4M
CELC [@Biotechnology] is valued at $524.83M. CLRB’s [@Biotechnology] market capitalization is $14.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $300.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileCLRB’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 4 TA indicator(s) are bullish while CLRB’s TA Score has 5 bullish TA indicator(s).

  • CELC’s TA Score: 4 bullish, 4 bearish.
  • CLRB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CELC and CLRB are a good buy in the short-term.

Price Growth

CELC (@Biotechnology) experienced а +2.59% price change this week, while CLRB (@Biotechnology) price change was +3.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.56%. For the same industry, the average monthly price growth was +10.24%, and the average quarterly price growth was +39.21%.

Reported Earning Dates

CELC is expected to report earnings on Nov 17, 2025.

CLRB is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($525M) has a higher market cap than CLRB($14.4M). CELC YTD gains are higher at: 5.882 vs. CLRB (-43.813). CLRB has higher annual earnings (EBITDA): -45.92M vs. CELC (-114.96M). CLRB has less debt than CELC: CLRB (474K) vs CELC (98.7M). CELC (0) and CLRB (0) have equivalent revenues.
CELCCLRBCELC / CLRB
Capitalization525M14.4M3,646%
EBITDA-114.96M-45.92M250%
Gain YTD5.882-43.813-13%
P/E RatioN/AN/A-
Revenue00-
Total Cash206MN/A-
Total Debt98.7M474K20,823%
FUNDAMENTALS RATINGS
CELC vs CLRB: Fundamental Ratings
CELC
CLRB
OUTLOOK RATING
1..100
2353
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4397
P/E GROWTH RATING
1..100
10071
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (52) in the Miscellaneous Commercial Services industry is in the same range as CLRB (56) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's Profit vs Risk Rating (79) in the Miscellaneous Commercial Services industry is in the same range as CLRB (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as CLRB (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's Price Growth Rating (43) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for CLRB (97) in the Biotechnology industry. This means that CELC’s stock grew somewhat faster than CLRB’s over the last 12 months.

CLRB's P/E Growth Rating (71) in the Biotechnology industry is in the same range as CELC (100) in the Miscellaneous Commercial Services industry. This means that CLRB’s stock grew similarly to CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCCLRB
RSI
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 25 days ago
88%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AWACX23.40N/A
N/A
AB Wealth Appreciation Strategy C
EXHAX26.23N/A
N/A
Manning & Napier Pro-Blend Max Term S
FEYTX28.26N/A
N/A
Fidelity Advisor Asset Manager 85% M
ABYEX9.42N/A
N/A
AB Emerging Markets Multi-Asset Advisor
CCMMX9.61N/A
N/A
Conestoga Mid Cap Investors

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with IMNM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+0.58%
IMNM - CELC
45%
Loosely correlated
+15.12%
ABOS - CELC
45%
Loosely correlated
+5.34%
COGT - CELC
44%
Loosely correlated
+3.13%
RXRX - CELC
44%
Loosely correlated
+3.26%
RAPP - CELC
44%
Loosely correlated
+5.84%
More